Fosun Pharma (Stock Code: 600196.SH, 02196.HK) announced on May 28 that it has formally signed a Strategic Cooperation Framework Agreement with Chongqing Genrix Biopharmaceutical Co., Ltd. (Stock Code: 688443.SH, hereinafter "Genrix Bio"). Through a long-term, stable and mutually-trusted strategic partnership, both parties aim to accelerate the research, development, and commercialization of innovative drugs, while strengthening their core competitiveness and industry leadership.

As the first tangible outcome of this strategic cooperation, YaoPharma Co., Ltd. (hereinafter "YaoPharma"), a holding subsidiary of Fosun Pharma, has entered into an exclusive licensing agreement with Genrix Bio for the licensed product, namely pharmaceutical products containing Velinotamig (GR1803) as the sole active ingredient and/or a bispecific antibody co-targeting BCMA and CD3, as agreed upon by both parties. Under the terms of the agreement, YaoPharma will obtain the exclusive rights to the clinical development, manufacturing, and commercialization of GR1803 in Greater China (mainland China, Hong Kong, Macao, and Taiwan). This collaboration is intended to integrate the complementary strengths of both parties, accelerate the accessibility of this innovative therapy in China, and bring new treatment options to patients across the country.

GR1803 (Velinotamig) injection is designed to simultaneously bind to BCMA and CD3, with its affinity for BCMA being approximately two orders of magnitude higher than that for CD3. This asymmetric affinity design ensures that the bispecific antibody molecule can recruit and activate T cells to eliminate tumor cells, while effectively minimizing the non-specific T cell activation typically induced by CD3 binding, thereby reducing the in vivo toxicity and side effects of the GR1803 injection. The product's application for conditional marketing authorization was submitted to and accepted by the National Medical Products Administration (NMPA) in January 2026, and has been granted Priority Review status. In addition, clinical studies of the product in autoimmune diseases，such as systemic lupus erythematosus are progressing steadily. In May 2026, a subcutaneous formulation of GR1803 received NMPA approval to commence clinical trials for relapsed/refractory multiple myeloma, aiming to further improve treatment convenience and safety for patients.